BIOMAT Database Logo BIOMAT Database Logo

Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. 1995

F Kronenberg, and P König, and U Neyer, and M Auinger, and A Pribasnig, and U Lang, and J Reitinger, and G Pinter, and G Utermann, and H Dieplinger
Institute of Medical Biology and Human Genetics, University of Innsbruck, Austria.

Numerous studies have investigated lipoprotein(a) (Lp(a)) plasma concentrations in patients with ESRD, a patient group with an enormous risk for atherosclerosis. The reported differences in Lp(a) between controls and patients vary from a decrease of 49% to an increase of more than 1,000%. However, data are not consistent, mostly because of problems with statistical analysis, and only limited data are available for patients treated by continuous ambulatory peritoneal dialysis (CAPD). To estimate the significance of Lp(a) in ESRD and to demonstrate the statistical pitfalls concerning Lp(a) in case-control studies, a large multicenter study including 702 patients treated by either hemodialysis (HD) (N = 534) or CAPD (N = 168) was conducted, and results were compared with results from 256 healthy controls. Both patient groups showed significantly elevated Lp(a) levels in comparison with controls: 23.4 +/- 25.0 mg/dL (P < 0.005; HD) and 34.6 +/- 38.4 mg/dL (P < 0.0001; CAPD) versus 18.4 +/- 22.8 mg/dL (controls). CAPD patients showed significantly higher Lp(a) values than did patients treated by HD (P < 0.001). The difference between the two treatment groups possibly reflects an overproduction of Lp(a) to compensate for protein losses in CAPD patients. Both treatment groups included significantly more patients with Lp(a) values greater than the 75th percentile (25.6 mg/dL) of the control group (33.9 and 41.7% for HD and CAPD, respectively; P < 0.005). The higher Lp(a) values in patients were not explained by differences in isoform frequencies and the increase in Lp(a) was apolipoprotein(a) type specific: only patients with high-molecular-weight apolipoprotein(a) isoforms showed a significant elevation in Lp(a) levels. The increased plasma concentrations of Lp(a) may contribute to the high risk for atherosclerosis in ESRD, especially in patients treated by CAPD. Finally, it is believed that small sample sizes are responsible for the diverging results in Lp(a) literature.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010531 Peritoneal Dialysis, Continuous Ambulatory Portable peritoneal dialysis using the continuous (24 hours a day, 7 days a week) presence of peritoneal dialysis solution in the peritoneal cavity except for periods of drainage and instillation of fresh solution. CAPD,Continuous Ambulatory Peritoneal Dialysis
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

F Kronenberg, and P König, and U Neyer, and M Auinger, and A Pribasnig, and U Lang, and J Reitinger, and G Pinter, and G Utermann, and H Dieplinger
[Lipoprotein (a) in children with end stage renal failure on maintenance hemodialysis and continuous ambulatory peritoneal dialysis].
January 1997, Przeglad lekarski,
F Kronenberg, and P König, and U Neyer, and M Auinger, and A Pribasnig, and U Lang, and J Reitinger, and G Pinter, and G Utermann, and H Dieplinger
Sleep apnea in end-stage renal disease patients on hemodialysis and continuous ambulatory peritoneal dialysis.
January 1995, ASAIO journal (American Society for Artificial Internal Organs : 1992),
F Kronenberg, and P König, and U Neyer, and M Auinger, and A Pribasnig, and U Lang, and J Reitinger, and G Pinter, and G Utermann, and H Dieplinger
Transplantation, hemodialysis, and continuous ambulatory peritoneal dialysis for end-stage renal disease in diabetic patients.
January 1988, The Journal of diabetic complications,
F Kronenberg, and P König, and U Neyer, and M Auinger, and A Pribasnig, and U Lang, and J Reitinger, and G Pinter, and G Utermann, and H Dieplinger
Continuous ambulatory peritoneal dialysis in end-stage renal disease.
June 1983, Israel journal of medical sciences,
F Kronenberg, and P König, and U Neyer, and M Auinger, and A Pribasnig, and U Lang, and J Reitinger, and G Pinter, and G Utermann, and H Dieplinger
Efficacy of continuous ambulatory peritoneal dialysis combined with hemodialysis versus single hemodialysis in patients with end-stage renal disease.
January 2021, American journal of translational research,
F Kronenberg, and P König, and U Neyer, and M Auinger, and A Pribasnig, and U Lang, and J Reitinger, and G Pinter, and G Utermann, and H Dieplinger
Auto-immunity in patients with end-stage renal disease maintained on hemodialysis and continuous ambulatory peritoneal dialysis.
July 1983, Journal of clinical & laboratory immunology,
F Kronenberg, and P König, and U Neyer, and M Auinger, and A Pribasnig, and U Lang, and J Reitinger, and G Pinter, and G Utermann, and H Dieplinger
Continuous ambulatory peritoneal dialysis therapy for patients with end stage renal disease.
March 1990, Journal of gerontological nursing,
F Kronenberg, and P König, and U Neyer, and M Auinger, and A Pribasnig, and U Lang, and J Reitinger, and G Pinter, and G Utermann, and H Dieplinger
Sleep disorders in patients with end-stage renal disease undergoing dialysis: comparison between hemodialysis, continuous ambulatory peritoneal dialysis and automated peritoneal dialysis.
February 2015, International urology and nephrology,
F Kronenberg, and P König, and U Neyer, and M Auinger, and A Pribasnig, and U Lang, and J Reitinger, and G Pinter, and G Utermann, and H Dieplinger
Continuous ambulatory peritoneal dialysis for the end stage renal disease patients.
November 1986, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
F Kronenberg, and P König, and U Neyer, and M Auinger, and A Pribasnig, and U Lang, and J Reitinger, and G Pinter, and G Utermann, and H Dieplinger
A comparison of employment rates of patients treated with continuous ambulatory peritoneal dialysis vs in-center hemodialysis (Michigan End-Stage Renal Disease Study).
April 1989, Archives of internal medicine,
Copied contents to your clipboard!